靶向抑制MACIR表达或功能的抑制剂在制备肿瘤化疗增敏剂中的应用及其组合物
By targeting inhibitors that suppress MACIR expression or function, the problem of drug resistance to platinum-based chemotherapy drugs in ovarian cancer has been solved, the chemotherapy effect has been enhanced, and effective treatment of ovarian cancer has been achieved.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- NAT HEALTH COMMISSION INST OF SCI & TECH
- Filing Date
- 2026-04-09
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies have difficulty effectively targeting and inhibiting MACIR expression or function, leading to drug resistance issues in platinum-based chemotherapy drugs in tumors such as ovarian cancer, thus affecting the efficacy of chemotherapy.
Develop inhibitors that target and inhibit MACIR expression or function, such as siRNA, shRNA, antisense oligonucleotides, CRISPR/Cas systems, monoclonal antibodies, small molecule compounds, or peptide inhibitors, to block the interaction between MACIR and FIRRM, inhibit MACIR’s DNA binding ability, or downregulate its protein expression level, thereby enhancing the cytotoxicity of platinum-based chemotherapy drugs.
It significantly enhanced the sensitivity of ovarian cancer cells to platinum-based drugs, improved the efficacy of chemotherapy, overcame platinum resistance, and improved patient prognosis.
Smart Images
Figure CN122005819B_ABST